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Summary Between 1977 and 1993, 384 breast cancer patients were followed up post-operatively every 4 or 6 months with a serum tumour
marker panel (CEA-TPA-CA15-3) and the usual imaging techniques. Twenty-eight patients were treated 13.5±10 months (mean±s.d.) before
the clinical and/or radiological occurrence of distant metastases that were suspected because of an increase in the tumour markers (patients
treated 'early'). Their outcome was compared with that of 22 similar patients who were treated only after a definite radiological diagnosis was
achieved (patients treated 'not early'). The median survivals from mastectomy and salvage treatment were also compared forthe two groups.
The groups were similar for all the major prognostic factors (menopause, staging, hormone dependency). In the group treated 'early', the lead
time from the tumour marker increase to the clinical and radiological signs of metastases was significantly longer than that of the group not
treated 'early' (13.5 ± 10 vs 3.4 ± 2.8 months respectively; P< 0.001 by unpaired t-test). For patients treated 'early', the survival curves up to
30 months after salvage treatment and up to 72 months after mastectomy showed greater survival than those for the patients treated later
(42.9% vs 13.6% and 42.9% vs 22.7% respectively; P= 0.04 in both instances). These data suggest that treatmenttriggered by rising tumour
markers before clinical and/or radiological appearance of distant metastases can be useful in prolonging both the asymptomatic interval and
the duration of response of some relapsed patients. Randomized prospective trials must be encouraged to confirm these data and to better
evaluate the effect on the disease-free survival (DFS) and overall survival (OS) of 'early' salvage treatment protocols.
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Thus far, the reported studies on the post-operative follow-up of
breast cancerpatients have not shown any clearbenefit; the cost is
high and some data suggest that no significant improvement in the
survival occurs if relapses are diagnosed by imaging techniques
before the appearance of clinical signs (Adair et al, 1974; Bishop
et al, 1979; Horton, 1984; Ciatto et al, 1985; Andreoli et al, 1987).
As we have previously reported, post-operative monitoring with
the CEA-TPA-Cal5-3 association showed 87% sensitivity for the
early diagnosis ofdistant metastases. In some patients, these three
tumour markers increased a few months before the definite (i.e.
clinical and/or radiological) signs of relapse (Nicolini et al, 1989,
1991a and b). The ability to identify metastases by tumour
markers earlier than by radiological or physical examination
induced us to examine whether more prompt therapy could benefit
these patients. The aim ofthis study was to compare the lead time
from tumour marker increase to the clinical and radiological signs
of metastases and survivals from mastectomy and salvage treat-
ment in patients treated 'early', i.e. at a time of elevated tumour
markers and negative radiological (radiography, bone scintig-
raphy, liver echography) clinical findings, and in patients treated
conventionally at the time of positive radiological and/or clinical
findings.
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MATERIALS AND METHODS
Patients and follow-up study
From 1977 to 1993, 384 breast cancer patients were serially
followed up after mastectomy. Seventy-nine patients (20.6%)
withdrew from the follow-up protocol. The main characteristics of
patients studied are shown in Table 1. Patients who were N+ or
progestogen receptor negative at post-operative examination (249,
64.8%) underwent follow-up visits every 4 months, N- patients
(135, 35.1%) every 6 months. In relapsed patients, the frequency
of follow-up visits varied according to response to treatment.
Initially, serum CEA plus successively TPA and Cal5-3 determi-
nations, routine blood tests (ESR, glucose, calcium, phosphorus,
blood cell count, BUN, creatinine, GOT, GPIT, gamma GT,
bilirubin, alkaline phosphatase, immunoglobulins), skeletal radio-
graphy, chest radiography, bone scanning (BS), liver echography
in addition to a detailed history and clinical examination were
carried out to define the post-operative staging. Serial determina-
tions of the tumour marker panel, history, routine laboratory and
clinical examinations were performed at each follow-up visit,
while BS and liver echography were performed regularly at
24-month intervals. As in many relapsed patients the increase in
the CEA-TPA-Cal5-3 panel preceded clinical and radiological
signs of relapse (Nicolini et al, 1991b), this study was planned to
detect a significant number of 'early' relapses and thus more
rapidly initiate salvage treatment of metastatic disease. When the
tumour marker panel did not lead to suspicion of a relapse, the
follow-up plan was not altered. In the case of a constant elevation
(CE) (two consecutive elevated values for 2-4 weeks showing an
increase lower than 30%) and/or progressive increase (PI) (two
consecutive elevated values showing an increase 30%) ofat least
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Table 1 Clinical data in study group
Patients (n = 384) Stage 0 (n = 6) Stage I (n = 106) Stage II (n = 240) Stage IlIl (n = 32)
Age (years)
Mean (± s.d.) 53 ±14.5 55.3 ±11.8 53.1 ± 12.2 60±118
Range 33-68 29-80 25-81 34-84
Menopause
Post 4 70 172 26
Pre 2 36 68 6
Mastectomy
Radical 2 2 9 0
Modified radical 2 76 208 32
Quart 2 28 23 0
Primary size
Tus 6 -
Ti - 106 77 1
T2 - - 160 7
T3 - 3 10
T4 - - - 14
N+ - - 151 29
N 6 106 89 3
Follow-up (months)
Median 73 86 76 60
Range 56-127 12-192 14-210 19-276
Adjuvant therapy
Radiotherapy 16 7 2
Chemotherapy 1 20 5
Chemotherapy plus tamoxifen - 1 62 9
Tamoxifen 3 47 115 16
None 3 41 36
Receptor status
Er+ 1/2 28/51 56/106 12/22
Pr+ 1/2 16/51 40/106 10/22
Unknown 4 55 134 10
TNM, according to American Joint Committee on Cancer Staging (AJCC, 1983) and International Union Against Cancer (UICC, 1974). Post-menopause, atleast
24 months since last menstrual period; Er+, oestrogen receptor positive; Pr+, progestogen receptor positive. Tis, carcinoma in situ.
one marker that was unexplained by a clear concomitant benign
pathology or a constantly progressive increase (of at least two
sequential PI in one or more markers), in spite of a concomitant
known benign pathology, the patient was suspected of having
relapsed. and standard investigations of the organs commonly
involved by metastatic spread (bone, liver, lung) were immediately
carried out to confirm this suspicion and define the site ofrelapse.
Since 1981 we have managed volunteer patients by 'early'
salvage treatment. Fifty-two relapsed patients were recruited from
March 1981 to August 1992. Two patients were excluded because
of rapidly progressive metastasization that did not permit the
evaluation ofany treatment. Twenty-eight patients (54%) received
6early' salvage treatment. Eighteen of these 28 patients had been
given tamoxifen since mastectomy at a time when tumour markers
were negative. During post-operative follow-up, they were
suspected of relapse 4-78 months after mastectomy (Table 3).
They were included in the 'early' treated group (subgroup a). In
this subgroup a, at the time oftumour marker increase, all medical
imaging examinations (chest radiography, BS, liver echography)
for the diagnosis ofmetastases were negative in all but one patient
with an equivocal BS finding. In all these 18 patients, tamoxifen
was replaced by progestogen. The remaining ten patients in the
group treated 'early' were not receiving any therapy when they
were suspected of relapse by means of tumour markers alone
(subgroup b), and at that time they underwent first-line hormone
therapy (n = 8) or chemotherapy (n = 2) as salvage therapy.
Standard investigations were negative in allbutthree with equivocal
BS findings.
The 22 patients not treated 'early' at relapse were first treated
only after radiological confirmation of metastases (group c). In 2
(9%) of these 22 patients, no increase in tumour marker occurred
at the time of relapse; liver echography and chest radiography
were the first positive studies. In one patient, the tumour marker
increase was contemporaneous with pathological liver echo-
graphy. In the 19 remaining patients, at the time oftumour marker
increase, all standard investigations were negative but for one
patient with an equivocal BS finding. An informed consent to start
'early' salvage therapy before clinical and radiological signs of
distant metastases was the only criterion for recruitment to group
a+b or group c.
The main characteristics ofpatients treated 'early' (subgroups a,
b and group a+b) and patients not treated 'early' (group c) are
shown in Table 2. In the overall evaluation of the prognostic
factors, subgroup a and group a+b were similar to group c.
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Table 2 Clinical data in patients treated 'early' and not treated 'early'
Treated 'early' Not treated 'early'
Subgroup a (n = 18) Subgroup b (n = 10) Group a+b (n = 28) Group C (n = 22)
Age (years)
Mean (±s.d.) 58.8 ± 11.3 55.7 ± 9.2 57.7 ± 10.5 54.1 ±13
Range 34-78 43-69 34-78 32-77
Follow-up (months)
Mean (±s.d.) 64.6 ± 26.5 82.4 ± 31.1 71 ± 29 57.9± 43.4
Range 28-113 33-137 28-137 9-144
Menopause (n)
Pre 4 2 6 8
Post 14 8 22 14
Mastectomy (n)
Radical 2 - 2 2
Modified radical 15 10 25 16
Quart 1 - 1 4
Primary size (n)
T1-T2 13 9 22 21
T3-T4 5 1 6 1
N+ 16 6 22 14
N- 2 4 6 8
Adjuvant therapy (n)
Radiotherapy - - - 4
Chemotherapy - 1 2. 9
Chemotherapy plus tamoxifen 8 1 9 0
Tamoxifen 10 7 16 4
None - 1 1 5
Receptor status (n)
Er+ 7/13 3/3 10/16 3/7
Pr+ 4/13 2/3 6/16 2/7
Unknown 5 7 12 15
Site of distant metastases (n)
Bone 8 6 14 10
Visceral 9 3 12 10
Bone and visceral 1 1 2 2
Er+, oestrogen receptor positive; Pr+, progestogen receptor positive
Table 3 Time from surgery to tumour marker increase (TMi), time from TMi to relapse (clinical and/or radiological signs) and median survival (months) from
mastectomy and from salvage treatment in 28 patients treated 'early' and in 22 patients not treated 'early'
Patients treated 'early' Patients not treated 'early'
On tamoxifen since mastectomya Under no therapyb Group cc
Months from Median survival from Months from Median survival from Months from Median survival from
Surgery TMi to Mastectomy Salvage Surgery TMi to Mastectomy Salvage Surgery TMi to Mastectomy Salvage
to TMi relapse therapy to TMi relapse therapy toTMi relapse therapy
Median 26.5 8 60 24.5 39.5 15.5 78.5 31.5 27 3 44.5 15
Range 4-78 0.5-43 28-113 6-69 17-96 0.5-36 33-137 15-38 3-91 0-11 8-144 1-76
aSubgroup a, n = 18. bSubgroup b, n = 1 O.c n = 22. Months from TMi time to relapse (mean ± s.d.): group a + b, 13.5 ± 10; group c, 3.4 ± 2.8 (P< 0.001,
unpaired t-test).
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Figure 1 Survivals from mastectomy in 28 patients treated 'early'
(group a + b) and in 22 patients not treated 'early' (group c)
Methods
Serum TPA, CEA and Ca 15-3 concentrations were measured by
commercial kits (Sangtec Medical, Bromma, Sweden; Lepetit
Lysophase RIA, Milano; Sorin Biomedica, Saluggia, Italy; IRMA,
Cis International); their upper limit was > 60 mU ml-' and
subsequently >85 mU ml- for TPA, > 7 ng ml-l for CEA and
> 32 U ml for Ca 15-3.
Radiological examinations (skeletal and chest radiography, liver
echography) and BS were performed with conventional tech-
niques. The principal criteria for interpretation of BS results were
as previously reported (Nicolini et al, 1989).
Hormone receptors were measured using the dextran-coated
charcoal (DCC) method, and results were given in femtomoles
per milligram (fmol mg-') ofcytosol protein. The cut-offlevel was
3 fmol mg-'.
Statistical analysis
Median and range were evaluated from mastectomy to tumour
marker increase and from tumour marker increase to relapse.
Median survival was evaluated from the times of mastectomy and
salvage treatment. All these parameters were analysed separately
in patients treated 'early' who were or were not receiving therapy
when they were suspected for relapse (subgroups a and b) and in
patients treated 'not early' (group c).
Times from mastectomy to tumour marker increase, the lead
time from the suspicion ofrelapse on the basis of tumour markers
to the clinical and/or radiological signs of metastases between
patients treated 'early' and not treated 'early' were compared
using the unpaired t-test.
Overall survival curves from mastectomy and from salvage
treatment of patients treated 'early' and not treated 'early' were
generated using the Kaplan-Meier method (Kaplan and Meier,
1958). Differences between survival curves were tested with the
Mantel-Haenzsel statistic. The Cox proportional hazards regres-
sion analysis (BMDP 2L, Department of biomathematics,
University of California at Los Angeles, USA, revised 1990) was
used to examine whether any variable was an independent
predictor of survival. Variables selected for examination were age
(continuous values) menopausal status, surgery, staging, treatment
delivered 'early' and not delivered 'early'. The overall observation
Figure 2 Survivals from salvage therapy in 28 patients treated 'early'
(group a + b) and in 22 patients not treated 'early' (group c)
periods from salvage treatment and from mastectomy were 76 and
144 months, respectively, and the last death occurred within these
intervals. Survival curves were drawn and interrupted 30 and 72
months from the beginning, i.e. after most events had occurred,
and the statistical difference began to decrease progressively,
probably because ofthe small residual samples (Figures 1 and 2).
As regards patients treated 'early', only OS curves of group a+b
were compared with those of the group not treated 'early'.
Following recent recommendations (Black and Welch, 1993) the
mean lead time (3.4 months) observed in the 22 patients with
conventional radiological examination-based diagnoses of metas-
tases was subtracted from the time interval from salvage therapy to
death for each one of the 28 patients treated 'early'; the resulting
time intervals were used to build up the OS curve from salvage
treatment for the 28 patients treated 'early' (Figure 2).
RESULTS
Clinical outcome
Thus far, 56 (15%) patients have died, but for four patients (three
N- and one N+) death was apparently due to reasons other than
metastatic spread. Specifically, in three patients, the likely cause of
death was another cancer (one pancreatic, one hepatic cancer in
cirrhosis and one colorectal cancer), and in the fourth patient it
was cirrhosis.
Disease recurrences occurred in 65 patients; 13 ofthese patients
belonged to the group of 79 patients who withdrew from the
follow-up protocol and two others were excluded as a result of
rapidly progressive disease. Recurrences in the 50 patients
followed were: at distant sites only, 34; at distant sites and loco-
regional, 16 (11 in the group treated 'early' and five in the group
treated 'not early'). In 48 (96%) ofthese 50 relapsed patients with
distant or distant and locoregional metastases, the increase in
tumour marker preceded (n = 47) or occurred contemporaneously
(n = 1) with the diagnosis made by standard investigations.
Reliability of tumour markers and imaging techniques
The increase in one or more of the three markers preceded the
appearance ofthe clinical and/or radiological signs ofrelapse in 47
ofthe 50 (94%) patients evaluated. However, in 5 (10.6%) ofthese
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47 patients, an equivocal BS finding occurred earlier, and the bone
abnormalities were confirmed by computerized tomography or
skeletal radiography directed at the tracer avid areas on BS 4.5 ± 4
(mean ± s.d.) months after CE or PI of one or more markers had
occurred. In two of the three remaining patients, no increase in
tumour marker was found at the time of relapse. In one of these
cases, liver echography and, in the other, chest radiography were
the first pathological finding. In the last case, the increase in one or
more markers was contemporaneous with the appearance ofradio-
logical signs of metastases. In the 200 non-relapsed patients
followed-up at 4-month intervals, the specificities of CEA, TPA,
Cal5-3 and the CEA-TPA-Cal5-3 panel were 97%, 93%, 98%
and 89% respectively. In the 119 remaining patients who under-
went follow-up visits at 6-month intervals, the specificities were
97.5%, 96%, 99% and 93% respectively. With regard to the
imaging techniques, the specificities of skeletal radiography, liver
echography and BS were 97%, 98% and 59% respectively.
Evaluation of 'early' salvage treatment
Table 3 shows in subgroups a, b and in group c the median and range
ofthe time from mastectomy to tumour marker increase and from an
increase in tumour marker to the definite radiological and clinical
signs ofmetastases. In addition, it shows survivals frommastectomy
and salvage therapy. The time from mastectomy to tumour marker
increase was not significantly different between patients treated
'early' (subgroups a and b) andpatients treated 'notearly' (group c).
In subgroups a and b, the mean lead time from tumour marker
increase to relapse was significantly longer (P<0.001; unpaired
t-test) than that in group c. In the patient groups treated 'early'
(subgroups a and b), median survivals from mastectomy and from
salvage treatment were 60, 78.5 and 24.5, 31.5 months respectively.
In group c, the median survivals from mastectomy and from salvage
treatment were 44.5 and 15 months respectively.
Figure 1 shows the survivals from mastectomy in patients
treated 'early' (group a+b) and patients not treated 'early' (group
c). The two groups show similar survivals in the first 30 months.
Thereafter, the decrease in survival appears to be more rapid in the
patients not treated 'early'. In fact, 72 months after mastectomy,
the fraction of survivors is 42.9% in patients treated 'early' and
22.7% in patients not treated 'early'. The difference is statistically
significant (P = 0.041).
Figure 2 shows survival from salvage therapy in the same two
groups. In both groups, the decrease in survival is progressive and
linear but it is faster in group c. In fact, after 30 months of obser-
vation, the survivals are 42.9% in the 'early' treated group and
13.6% in the group treated later. The difference between these two
values is statistically significant (P = 0.045). Using the Cox
proportional hazards regression analysis, only early delivery of
treatment proved to be a highly significant variable.
DISCUSSION
Thus far, clinical studies that fail to find clear benefits from post-
operative monitoring of breast cancer patients have been
performed using conventional means (i.e. physical examination,
routine laboratory and/or radiological examinations) and have
excluded a role for tumour markers (Adair et al, 1974; Bishop et
al, 1979; Horton, 1984; Ciatto et al, 1985; Andreoli et al, 1987).
Two recent trials (Dixon et al, 1993a and b) have shown a role for
tumour markers in guiding therapy and in the monitoring of
the response to treatment of metastatic breast cancer patients.
Furthermore, the observation that the growth rate of distant metas-
tases is faster than in the primary tumour (Tubiana and Koscienly,
1988) suggests that an 'early' detection and treatment of distant
metastases might be helpful. Our study used for the first time the
measurement of a sensitive tumour marker panel for 'early' detec-
tion ofdistant metastases. This approach was useful as 47 (94%) of
the 50 relapsed patients were detected 'early', i.e. before the
appearance of radiological and/or clinical findings. This allowed
the initiation of 'early' salvage treatment. In relapsed patients
subjected to 'early' treatment, the lead time from the increase in
tumour marker to the appearance of radiological signs of metas-
tases was significantly prolonged (P < 0.001; unpaired t-test).
During this interval, no or only minor symptoms occurred. As the
increase in tumour marker is likely to warn of the risk of progres-
sion to overt metastatic disease, the prolongation of this time
suggests that 'early' treatment in responsive patients slows or
temporarily halts disease progression so as to delay the appearance
of radiological signs. In patients treated 'early', median survival
from salvage treatment and from mastectomy was prolonged when
compared with that of patients treated only after metastases were
ascertained by radiological means. The prolongation ofthe former
interval might be considered misleading and due to the beginning
of salvage treatment 'early' (Horton, 1984; Ciatto et al, 1985;
Tomin and Donogan, 1987; Rutgers et al, 1989; Del Turco et al,
1994; Givio, 1994). This is the so-called lead time bias.
Nevertheless, the prolongation of median survival from mastec-
tomy, i.e. a stable end point, suggests that in patients treated 'early'
and in respongive patients the prolongation ofthe interval from the
time of tumour marker increase to the definite signs ofmetastases
really does prolong both median survivals.
These concepts are confirmed by comparison of the survival
curves from both the time of mastectomy and from salvage treat-
ment. In fact the difference between the two curves from mastec-
tomy is statistically significant, and that between the two curves
from salvage therapy attains statistical significance even after the
subtraction in the 28 patients treated 'early' of the mean lead time
observed in the 22 patients treated not 'early'. As to the length bias
that pertains to comparisons unadjusted for the rate ofprogression
of disease (Black and Welch, 1993), it is not likely to affect the
results of the study. In the groups a+b and c, the main prognostic
indices were similar (Table 2). These findings are apparently in
contrast with those so far reported in clinical studies with regard to
the use of the post-operative follow-up of breast cancer patients.
However, in most of these studies, tumour markers were not used
at all or were not used with precise criteria to define the 'early'
detection of distant metastases (Adair et al, 1974; Bishop et al,
1979; Horton 1984; Ciatto et al, 1985; Andreoli et al, 1987; Tomin
and Donogan, 1987; Rutgers et al, 1989; Del Turco et al, 1994;
Givio 1994). In our study, the criteria used for interpreting tumour
marker levels together with the history and routine laboratory
examinations at each follow-up visit kept the number of false-
positive diagnoses ofdistant metastases to a minimum, simultane-
ously leading to a great saving in the number of radiological
examinations.
Recently, some advantages ofthe 'early' detection ofrecurrences
by measurement of tumour markers and the early use ofhormonal
therapy for treatment of low tumour burdens have been reported
in the management of cancers other than breast. In fact, in a
meta-analysis on the post-operative follow-up of colorectal cancer
patients, studies with intensive follow-up that included serial serum
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CEA assays revealed a higher rate of detection of asymptomatic
tumours and radically resectable recurrences as well as a 9% better
5-year survival than did those series with minimal or no follow-up
(Bruinvels et al, 1994). Similarly, a longer survival of prostate
cancer patients is reported when hormonal therapy is initiated early
in locally advanced disease (Einstein, 1995). In these patients,
serial serum PSA determinations contribute to the 'early' detection
and lower tumour burden ofprimary tumour.
Data from this study in breast cancer patients suggest that
'early' salvage therapy can delay disease progression of relapsed
patients and that tumour markers play an important role for this
purpose. In fact, determination of appropriate circulating tumour
markers allows a simple and adequate follow-up as well as an
'earlier' identification of relapsed patients. We hope that this
report will stimulate randomized prospective trials on the effect of
early salvage treatment ofbreast cancer patients.
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